Skip to main content
Premium Trial:

Request an Annual Quote

GigaGen Gets More Than $1M in Grants to Develop Cell-Seq Technology

NEW YORK (GenomeWeb News) – Genetics-based diagnostic company GigaGen today said that it has received four grants totaling more than $1 million to develop and validate its Cell-Seq technology to aid in the prediction of immune flares in transplant recipients and autoimmune patients.

The grants are from the National Institutes of Health and the National Science Foundation. Three will go toward the development, validation, and characterization of the San Francisco-based company's Cell-Seq technology, which measures genotype and expression of dozens of target genes across millions of single cells, GigaGen said. The technology enables massively parallel single-cell genetic analysis.

The fourth grant will be used to develop web-based tools for processing, analyzing, and visualizing Cell-Seq data.

Using microfluidics and next-generation sequencing, the Cell-Seq technology will be the first to empower physicians to monitor a patient's disease-specific immune activity and provide care on a personalized basis to prevent and treat immune flares, GigaGen said, adding it expects to commercialize its first clinical test in 2013 at leading academic medical centers.

Earlier this year GigaGen and Dolomite announced a deal to co-develop a droplet merger chip for massively parallel single cell genetic analysis.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.